CLAIMS

1. A pharmaceutical composition comprising VS-6063, or a pharmaceutically acceptable salt thereof, admixed with polyvinylpyrrolidone vinyl acetate copolymer (PVP VA) and a copolymer comprising polyethylene glycol, polyvinylcaprolactam, and polyvinylacetate, wherein the composition is configured in an oral dosage form.

2. The pharmaceutical composition of claim 1, wherein the oral dosage form comprises 5 to 50%, 5 to 30%, 10 to 30%, 10 to 20%, 12 to 15%, or 13% of VS-6063, or a pharmaceutically acceptable salt thereof, per weight of the oral dosage form.

3. The pharmaceutical composition of claim 1, wherein the VS-6063, or a pharmaceutically acceptable salt thereof, is present at 13% per weight of the oral dosage form.

4. The pharmaceutical composition of claim 1, wherein the oral dosage form is a tablet.

5. The pharmaceutical composition of claim 4, wherein the tablet is provided by direct compression of a physical blend or mixture.

6. The pharmaceutical composition of claim 5, wherein the physical blend or mixture is provided by a dry granulation process.

7. The pharmaceutical composition of claim 1, further comprising a disintegrant.

8. The pharmaceutical composition of claim 7, wherein the disintegrant is crosslinked polyvinylpyrrolidone or crospovidone, carboxymethyl cellulose or croscarmellose sodium, or a modified starch.

9. The pharmaceutical composition of claim 7, wherein the disintegrant is a polyvinylpolypyrrolidone.

10. The pharmaceutical composition of claim 7, wherein the disintegrant is present at 0 to 30%, 5 to 25%, 5 to 20%, 5 to 15%, or 10% per weight of the oral dosage form.

11. The pharmaceutical composition of claim 1, further comprising a lubricant.

12. The pharmaceutical composition of claim 11, wherein the lubricant is talc, silica, or fats, optionally wherein the lubricant is magnesium stearate, optionally wherein the lubricant is present at 0.1 to 2%, 0.2 to 1.5%, 1%, or 0.5% per weight of the oral dosage form.

13. The pharmaceutical composition of claim 1, further comprising one or more fillers.

14. The pharmaceutical composition of claim 13, wherein the filler is a polyol.

15. The pharmaceutical composition of claim 14, wherein the polyol is mannitol-starch, mannitol, or sorbitol.

16. The pharmaceutical composition of claim 1, wherein the composition comprises VS-6063 free base or VS-6063 hydrochloride.

17. An oral dosage form comprising:

VS-6063, or a pharmaceutically acceptable salt thereof, in an amount from 10 to 15% by weight on a dry weight basis,

a first pharmaceutically acceptable excipient in an amount from 15 to 25% by weight on a dry weight basis, wherein the first pharmaceutically acceptable excipient is polyvinyl pyrrolidone vinyl acetate copolymer (PVP VA),

a second pharmaceutically acceptable excipient in an amount from 15 to 25% by weight on a dry weight basis, wherein the second pharmaceutically acceptable excipient is a copolymer comprising polyethylene glycol, polyvinylcaprolactam, and polyvinylacetate,

a pharmaceutically acceptable filler in an amount from 30 to 40% by weight on a dry weight basis,

a pharmaceutically acceptable disintegrant in an amount from 5 to 15% by weight on a dry weight basis, and

a pharmaceutically acceptable lubricant in an amount from 0.2 to 1.5% by weight on a dry weight basis.

~~18. The oral dosage form of claim 17, wherein the first pharmaceutically acceptable excipient is polyvinyl pyrrolidone vinyl acetate copolymer (PVP VA).~~

~~19. The oral dosage form of claim 17, wherein the second pharmaceutically acceptable excipient is a copolymer comprising polyethylene glycol, polyvinylcaprolactam, and polyvinylacetate.~~

~~20~~18. The oral dosage form of claim 17, wherein the pharmaceutically acceptable filler is mannitol-starch.

~~21~~19. The oral dosage form of claim 17, wherein the pharmaceutically acceptable disintegrant is crospovidone.

~~22~~20. The oral dosage form of claim 17, wherein the pharmaceutically acceptable lubricant is magnesium stearate.